Salivary pH as a marker of plasma adiponectin concentrations in Women

Diabetology & Metabolic Syndrome

Daniel Gaudet¹  Diane Brisson¹  Julie Methot¹  Yacine Loucif¹  Monique Tremblay¹ 

[1] Department of Medicine, Université de Montréal, ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, Saguenay, QC, Canada

关键词: Diabetes;    Cardiometabolic risk;    Adiponectin;    Salivary pH;   

Others  :  817448
DOI  :  10.1186/1758-5996-4-4

 received in 2011-08-24, accepted in 2012-02-03,  发布年份 2012

【 摘 要 】

Background

Plasma adiponectin is a significant correlate of the pro-inflammatory cardiometabolic risk profile associated with obesity and type 2 diabetes. Salivary pH is influenced by several cardiometabolic risk components such as inflammation, oxidation and numerous oral and systemic health modulators, including the menopausal status. This study aimed to assess the association between plasma adiponectin concentrations and salivary pH in women according to the menopausal status.

Method

Unstimulated saliva collection was performed in 151 Caucasian women of French-Canadian origin (53 premenopausal women (PMW) and 98 menopausal women (MW)). Student's t test, ANOVA and linear regression models were used to assess the association between plasma adiponectin concentrations and salivary pH.

Results

Plasma adiponectin levels increased as a function of salivary pH in the whole sample and among MW (r = 0.29 and r = 0.36, p < 0.001). The proportion of the variance of plasma adiponectin levels explained by the salivary pH (R²) was 10.8% (p < 0.001). Plasma adiponectin levels progressively increased across salivary pH quartiles (p = 0.005).

Conclusions

These results suggest that salivary pH is a significant correlate of plasma adiponectin levels in women. With the increasing prevalence of type 2 diabetes and obesity, new technologies should be developed to more easily monitor health status, disease onset and progression. Salivary pH, a simple, inexpensive and non-invasive measure, could be a very promising avenue.

【 授权许可】

   
2012 Tremblay et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]WHO WHO: Obesity and overweight. 2008.
• [2]Borch-Johnsen K: The metabolic syndrome in a global perspective. The public health impact--secondary publication. Dan Med Bull 2007, 54(2):157-159.
• [3]Tarquini R, Lazzeri C, Laffi G, Gensini GF: Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med 2007, 2(3):165-176.
• [4]Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120(4):803-812.
• [5]Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360(9326):57-58.
• [6]Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86(5):1930-1935.
• [7]Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H: Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res 2008, 31(2):229-233.
• [8]Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52(2):239-243.
• [9]Odrowaz-Sypniewska G: Markers of pro-inflammatory and pro-thrombotic state in the diagnosis of metabolic syndrome. Adv Med Sci 2007, 52:246-250.
• [10]Chiappin S, Antonelli G, Gatti R, De Palo EF: Saliva specimen: a new laboratory tool for diagnostic and basic investigation. Clin Chim Acta 2007, 383(1-2):30-40.
• [11]Humphrey SP, Williamson RT: A review of saliva: normal composition, flow, and function. J Prosthet Dent 2001, 85(2):162-169.
• [12]Sreebny LM: Saliva in health and disease: an appraisal and update. Int Dent J 2000, 50(3):140-161.
• [13]Lukacs JR, Largaespada LL: Explaining sex differences in dental caries prevalence: saliva, hormones, and "life-history" etiologies. Am J Hum Biol 2006, 18(4):540-555.
• [14]Mata AD, Marques D, Rocha S, Francisco H, Santos C, Mesquita MF, Singh J: Effects of diabetes mellitus on salivary secretion and its composition in the human. Mol Cell Biochem 2004, 261(1-2):137-142.
• [15]Carda C, Mosquera-Lloreda N, Salom L, Gomez de Ferraris ME, Peydro A: Structural and functional salivary disorders in type 2 diabetic patients. Med Oral Patol Oral Cir Bucal 2006, 11(4):E309-314.
• [16]Dodds MW, Dodds AP: Effects of glycemic control on saliva flow rates and protein composition in non-insulin-dependent diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997, 83(4):465-470.
• [17]Streckfus C, Bigler L, O'Bryan T: Aging and salivary cytokine concentrations as predictors of whole saliva flow rates among women: a preliminary study. Gerontology 2002, 48(5):282-288.
• [18]Jurysta C, Bulur N, Oguzhan B, Satman I, Yilmaz TM, Malaisse WJ, Sener A: Salivary glucose concentration and excretion in normal and diabetic subjects. J Biomed Biotechnol 2009, 2009:430426.
• [19]Toda M, Tsukinoki R, Morimoto K: Measurement of salivary adiponectin levels. Acta Diabetol 2007, 44(1):20-22.
• [20]Katsiougiannis S, Tenta R, Skopouli FN: Activation of AMP-activated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon-gamma-induced apoptosis. Arthritis Rheum 2010, 62(2):414-419.
• [21]Lohman TG, Roche AF, MR : Standardization of anthropometric measurements. In The Airlie (VA): 1988; Champaign, IL Edited by Lohman TRA, Martorel R. 1988, 39-80. Consensus Conference
• [22]American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003, 26(Suppl 1):S33-50.
• [23]Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955, 34(9):1345-1353.
• [24]Katsiougiannis S, Kapsogeorgou EK, Manoussakis MN, Skopouli FN: Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum 2006, 54(7):2295-2299.
• [25]Wong DT: Salivary diagnostics. J Calif Dent Assoc 2006, 34(4):283-285.
• [26]Lappas M, Permezel M, Rice GE: Leptin and adiponectin stimulate the release of proinflammatory cytokines and prostaglandins from human placenta and maternal adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology 2005, 146(8):3334-3342.
• [27]Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361(9353):226-228.
• [28]Swarbrick MM, Havel PJ: Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008, 6(2):87-102.
• [29]Nagler RM: Salivary glands and the aging process: mechanistic aspects, health-status and medicinal-efficacy monitoring. Biogerontology 2004, 5(4):223-233.
• [30]Chavez EM, Borrell LN, Taylor GW, Ship JA: A longitudinal analysis of salivary flow in control subjects and older adults with type 2 diabetes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001, 91(2):166-173.
• [31]Li Y, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Wolinsky L, Wong DT: The Oral Fluid MEMS/NEMS Chip (OFMNC): diagnostic and translational applications. Adv Dent Res 2005, 18(1):3-5.